Apyx Medical Corporation (APYX), formerly known as Bovie Medical Corporation, is an advanced medical technology-specialized company that develops, manufactures, and markets various medical products and technologies. It is primarily known for innovation in the field of electrosurgery, developing high-frequency equipment capable of cutting and/or coagulating tissue. The company is based in Clearwater, Florida, and it was founded in 1978.
The core business of Apyx Medical Corp focuses on two primary areas. First, it manufactures and sells a range of electrosurgical products. These are primarily marketed under the Renuvion and J-Plasma brands, and they are used by clinicians in a variety of settings, including hospitals, surgical centers, and doctor's offices across the globe.
Renuvion is one of the products that has positioned the company in the aesthetics sector. It is used in cosmetic surgery, dermatology, and procedural dermatology. Renuvion delivers a helium plasma stream combined with radiofrequency (RF) energy to provide a unique thermal effect on tissues.
J-Plasma, on the other hand, is a plasma-based cutter and coagulator that combines cold helium plasma with RF energy. It generates a precise beam of energy that can be used for cutting, coagulating and ablating (removing) soft tissue. It is designed to minimize heat dispersion and thus avoid potential thermal injury during surgical procedures.
In addition to its product line, APYX also offers contract manufacturing services to companies in the medical device sector, providing OEM (Original Equipment Manufacturer) services for a range of medical products.
Apyx Medical Corporation has established itself as a key player in the medical technology industry. The company is dedicated to enhancing patient safety and improving surgical outcomes through its advanced technology platforms. In terms of financial performance, APYX has shown steady growth over the years. It is publicly traded on the NASDAQ stock exchange under the ticker symbol APYX.
The company's mission of improving the lives of patients and healthcare professionals aligns with its ongoing commitment to research, development, and innovation, setting the stage for its continuous growth in the medical technology sector.
In essence, Apyx Medical Corp highlights the intersection of innovation and healthcare, demonstrating the power of advanced technology in transforming medical procedures and positively impacting patient outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Apyx Medical is leveraging the increasing demand for surgical aesthetic procedures, driven by GLP-1 weight-loss drugs, with its Renuvion technology and new AYON Body Contouring System. The company projects significant revenue growth for 2026 in surgical aesthetics and is focusing on expanding its product offerings, pursuing international registrations, and achieving profitability. The AYON system, which combines multiple body contouring technologies, is expected to improve operating room efficiency and patient outcomes.
Apyx Medical reported a 22% increase in Q2 revenue, reaching $13.9 million, driven by strong surgical aesthetics sales, particularly from its AYON Body Contouring System. The company expanded FDA clearance for AYON to include power liposuction and expects over 95% of AYON buyers to adopt this new capability, generating recurring revenue. Apyx Medical narrowed its net loss and reaffirmed its 2026 revenue guidance of $59 million to $60 million, with a gross margin expectation of 62% to 63%.
HC Wainwright has lowered its Q3 2026 EPS forecast for Apyx Medical (NASDAQ: APYX) to a loss of $0.07 per share from $0.06, while maintaining a Buy rating and a $7.00 price target. Despite the lowered forecast, Apyx Medical recently reported earnings that beat expectations with a $0.07-per-share loss against a projected $0.08 loss and revenue of $13.88 million, exceeding the $13.18 million consensus. The stock was trading down 14.6% at $3.46, even though the company holds a MarketBeat consensus rating of "Moderate Buy" and an average analyst target price of $6.60.
Sei Investments Co. significantly increased its stake in Apyx Medical Corporation by 298.6% during the first quarter, purchasing an additional 448,174 shares to bring its total holdings to 598,255 shares, valued at $2.208 million. This move is part of broader institutional interest, with such investors now collectively owning 55.33% of Apyx Medical. The company recently surpassed quarterly earnings and revenue expectations, and analysts maintain a "Moderate Buy" consensus rating for the stock.
Apyx Medical Corporation (NASDAQ:APYX) has received a "Moderate Buy" consensus recommendation from seven brokerages, with an average 12-month price target of $6.60, significantly higher than its current $4.05 price. The company recently surpassed earnings estimates, reporting a smaller adjusted loss and higher revenue than expected. Despite strong institutional ownership (55.33%), Apyx Medical remains unprofitable, with negative net margin and return on equity.
Apyx Medical (NASDAQ:APYX) reported its quarterly earnings, beating analyst expectations with an adjusted loss of $0.07 per share against a projected $0.08 loss and revenue of $13.88 million. This revenue marked a 22% increase year-over-year, driven by a significant rise in surgical aesthetics sales and the initial rollout of its AYON PowerLipo system. Despite improved profitability metrics, the company continued to use cash, reaffirmed its 2026 revenue guidance, and faces margin pressure from tariffs.